Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04216446
Other study ID # 2019-0757-2504
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 13, 2020
Est. completion date July 2023

Study information

Verified date October 2022
Source Aga Khan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A parallel-group randomized controlled trial that will evaluate the efficacy of a mobile health (m-Health) program on influencing diet, supplement use and physical activity during pregnancy. Pregnant women will be randomly assigned to the intervention and the non-intervention arm. The intervention arm will receive free of cost m-Health application that will screen on the diet, supplement use and physical activity at enrollment and at 4 follow-ups, each 6 weeks apart. Based on the information provided by women, they will receive personalised recommendations based on an algorithm developed using the World Health Organization's guidelines on nutrition during pregnancy and American College of Obstetricians and Gynaecologists guidelines for physical activity during pregnancy. The non-intervention arm will receive standard face-face counselling. The changes in diet and supplement use of both groups will be assessed using the Dietary Risk Score. Also, biochemical assessment of micronutrients will be carried out on a subset. the change in physical activity will be assessed by the mean duration of reported activity. The secondary outcomes include the evaluation of compliance and usability of the m-Health application. Also, the effect of the m-Health application on maternal, newborn and infant outcomes will be assessed.


Description:

A parallel-group randomized controlled trial will be implemented with pregnant women at the antenatal clinics of the Aga Khan University Hospital (AKUH) Karachi. Pregnant women in their first trimester, registered or planning to register at AKUH with access to personal smartphones with internet connection will be considered eligible for the study. For pregnant women in the intervention arm, mobile health application will be provided on their smartphones that will screen their socio-demographic characteristics, diet and supplement use and physical activity habits. Based on the information provided by women, personalized recommendations and a dietary risk score will be generated upon completion of the questionnaire. A similar process will be repeated on 4 follow-ups, each 6 weeks apart after enrollment in the study. Also, push notifications consisting of tips and recommendations will be sent to women a maximum of 3 times a week on dietary, supplement use and physical activity. The women in the non-intervention arm will be provided with standard face-face counselling at similar time points as of intervention group, using the bilingual educational leaflet of the Aga Khan University Hospital "Diet during Pregnancy" and the American College of Obstetricians and Gynaecologists guidelines for physical activity during pregnancy. The primary outcome of the study is improvement in the dietary and supplement use that will be assessed through Dietary Risk Score. A selective subset of participants from both the group will undergo free of cost biochemical assessment micronutrients (serum calcium, vitamin D, iron and folate). The secondary outcomes include assessing the compliance and usability of m-Health application among the pregnant women enrolled in the intervention arm. Other secondary outcomes include evaluating the effect of m-Health coaching on maternal, newborn and infant outcomes among pregnant women in the intervention arm compared to the pregnant women in the non-intervention arm


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 306
Est. completion date July 2023
Est. primary completion date September 30, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Pregnant women 18 years and above in their first trimester 2. Enrolled at antenatal clinics of The Aga Khan University Hospital, Karachi 3. Pregnant women who have personal smartphones with internet connections. 4. Eligible subjects who consent to participate and agree to remain in the study until the first year of the birth of the baby. Exclusion Criteria: 1. Pregnant women who have co-morbidity such as cardiovascular disease, diabetes, liver or kidney disease or autoimmune disorder (SLE) 2. Pregnant women who are on dietary control due to co-morbid conditions. 3. Pregnant women who are on platelet aggregates, hypoglycemic or anti-hypertensive drugs. 4. Pregnant women who are unable to read and write due to the language barrier.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mobile Health Intervention
A mobile based application will be developed that will function on android as well as the iPhone operating system. The application will be provided to eligible pregnant women randomized to the intervention group. The dietary, supplement use and physical activity coaching will be provided over the period of 6 months through the application.

Locations

Country Name City State
Pakistan The Aga Khan University Karachi Sindh

Sponsors (1)

Lead Sponsor Collaborator
Aga Khan University

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dietary Risk Score (DRS) Dietary Risk Scores (DRSs) will be calculated based on the consumption of food items from six main food groups and will range from 0-18. Based on the portions and quality of diet, the score for each group will be 0, 1.5 or 3. The total score will be the sum of individual group scores. Higher the aggregate score, poorer the dietary quantity and quality and vice versa. Hence, a score of 18 will indicate a highly inadequate dietary intake; a score of 9 denotes nearly adequate and a score of 0, an adequate diet. 6 months, from enrollment till last follow-up
Primary Supplement use Score Supplement use will be assessed by recording the frequency of consumption of folic acid, iron, calcium and vitamin D in the questionnaire. The frequency will be categorized as daily (7 days a week), often (4-6 days a week) and sometimes (1-3 days a week). Also, a total score ranging from 0-12 will be assigned where each supplement use will be scored 0 for daily, 1.5 for less than daily and 3 for no consumption. The total score will be the sum of each supplement score and will be monitored at each follow-up. 6 months, from enrollment till last follow-up
Primary Biochemical Assessment of serum folate at baseline A subset of pregnant women from each group will be selected systematically for the biochemical testing of serum folate at the baseline screening 1 week of enrollment
Primary Biochemical Assessment of serum ferritin at baseline A subset of pregnant women from each group will be selected systematically for the biochemical testing of serum ferritin at the baseline screening 1 week of enrollment
Primary Biochemical Assessment of serum calcium at baseline A subset of pregnant women from each group will be selected systematically for the biochemical testing of serum calcium at the baseline screening 1 week of enrollment
Primary Biochemical Assessment of vitamin D at baseline A subset of pregnant women from each group will be selected systematically for the biochemical testing of vitamin D levels at the baseline screening 1 week of enrollment
Primary Biochemical Assessment of serum folate at endline screening A subset of pregnant women from each group will be selected systematically for the biochemical testing of serum folate at the end line screening. 24 week of enrollment
Primary Biochemical Assessment of serum ferritin at endline screening A subset of pregnant women from each group will be selected systematically for the biochemical testing of serum ferritin at the end line screening. 24 week of enrollment
Primary Biochemical Assessment of serum calcium at endline screening A subset of pregnant women from each group will be selected systematically for the biochemical testing of serum calcium at the end line screening. 24 week of enrollment
Primary Biochemical Assessment of Vitamin D at endline screening A subset of pregnant women from each group will be selected systematically for the biochemical testing of vitamin D levels at the end line screening. 24 week of enrollment
Primary Physical activity Intensity and duration (minutes) of physical activity will be assessed through the questionnaire at baseline and each follow-up. Household tasks such as cooking, ironing, light physical work, driving and washing dishes will be categorized as mild activities. Brisk walking, gardening, house hold chores such as sweeping, washing, mopping, actively playing with children and carrying loads <20kg will be classified as moderate intensity activities. On the other hand, vigorous intensity activities will include running, fast cycling, aerobics, swimming, sports games or carrying load >20 kg. 6 months, from enrollment till last follow-up
Secondary Compliance with the intervention Percentage of participants who would complete the six months' program. 24 week of enrollment
Secondary Usability of mobile health program Usability of the web-based program will be assessed at the end of the study using a digital evaluation form containing 26 questions with a five response categories Likert-type scale as strongly agree, agree, neutral, disagree and strongly disagree OR always, often, sometimes, rarely and never. it will be assessed under three categories: (i) design and interface, (ii) content and coaching and (iii) perception and personal benefit. 24 week of enrollment
Secondary Maternal health outcomes: Pre-eclampsia new onset of hypertension after 20 weeks of gestation along with proteinuria (a spot urine protein/creatinine ratio of =30 mg per mmol) and/or evidence of maternal acute kidney injury, liver dysfunction, neurological features, hemolysis or thrombocytopenia, and/or fetal growth restriction. Through study completion, average of 1 year
Secondary Maternal health outcomes: Gestational hypertension New onset of hypertension i.e. blood pressure =140 mmHg systolic or =90 mmHg diastolic at or after 20 weeks' gestation Through study completion, average of 1 year
Secondary Maternal health outcomes: Gestational Diabetes Diagnosis made by a single-step 75-g oral glucose tolerance test conducted between 24 and 28 weeks of gestation or at any other time, with one or more of the following results: (1) Fasting plasma glucose 5.1-6.9 mmol/L (92-125 mg/dL); (2) 1-hour post 75-g oral glucose load =10 mmol/L (180 mg/dL); (3) 2-hour post 75-g oral glucose load 8.5-11.0 mmol/L (153-199 mg/dL) Through study completion, average of 1 year
Secondary Maternal health outcomes: Gestational weight gain during first, second and third trimester Gestational weight gain (GWG) will be determined from weights recorded during the first, second and third trimester. Centiles and z-scores would be assessed using the international gestational weight gain calculator based on the INTERGROWTH-21st standards for gestational weight gain Through study completion, average of 1 year
Secondary Newborn birth weight Newborn birth weight in grams adjusted for gestational age at birth will be compared with INTERGROWTH-21st standards. Through study completion, average of 1 year
Secondary Newborn length Newborn length in cm adjusted for gestational age at birth will be compared with INTERGROWTH-21st standards. Through study completion, average of 1 year
Secondary Preterm birth Preterm births will defined as spontaneous births before completed 37 weeks of gestation. Through study completion, average of 1 year
Secondary Infant's Blood Pressure at 1 year Resting blood pressure (BP) would be assessed at 12 month age, after the infant had been calm for >3 min. Mean Systolic and Diastolic BP more than 90th centile appropriate for the height centile and gender will be considered high risk. 1 year of infant's age
Secondary Infant's Body Mass Index Infant's weight and length will be assessed at 12 month age. 1 year of infant's age
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02528136 - The Clinical Carbetocin Myocardium Trial Phase 4